MidDiagnosed 2026-10-02 15:25:39 KSTBBMRNAI Stock Diagnostic ReportBioMarin presents five-year data on Pompe disease treatmentBioMarin has announced 5-year clinical data for its Fabry disease treatment, but the impact on the stock price is assessed as neutral as the direction of the data is not clear.View Source Article ↗ AI CATALYST SCORE50 / 100Score computed by Sentinel V12REFERENCE PRICENot measuredReference entry price at analysis time 👍 0🔥 0🤔 0🔗 0𝕏f🔗📤